Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
ATP Driven Pumps III: V-type Pumps01:30

ATP Driven Pumps III: V-type Pumps

V-type pumps are ATP-driven pumps found in the vacuolar membranes of plants, yeast, endosomal and lysosomal membranes of animal cells, plasma membranes of a few specialized eukaryotic cells, and some prokaryotes. They are also known as the V1Vo-ATPase, that couple ATP hydrolysis to transport protons against a concentration gradient.
The peripheral or cytosolic V1 domain with eight subunits is involved in ATP hydrolysis. The integral or transmembrane V0 domain containing at least five subunits...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
ATP Driven Pumps II: P-type Pumps01:34

ATP Driven Pumps II: P-type Pumps

The P-type pumps are a large family of integral membrane transporter ATPases. They are divided into five major types based on substrate specificity, from I to V.
A typical P-type pump has three cytosolic domains: nucleotide-binding (N), phosphorylation (P), and activator (A) domains. These domains are connected to the membrane-spanning helices by short amino acid segments. ATP hydrolysis and covalent phosphoenzyme intermediate formation are crucial parts of the catalytic cycle. At the highly...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Synthesis, characterization, Hirshfeld surface analysis of V-substituted Keggin polyoxotungstates and Ca<sup>2+</sup>-ATPase inhibiting potential.

Journal of inorganic biochemistry·2026
Same author

Polyoxometalates in environmental remediation and energy storage.

Environmental science. Nano·2026
Same author

Special Issue: Emerging Topics in Metal Complexes: Pharmacological Activity, 2nd Edition.

International journal of molecular sciences·2025
Same author

Dawson- and Lindqvist-Type Hybrid Polyoxometalates: Synthesis, Characterization and Ca<sup>2+</sup>-ATPase Inhibition Potential.

Molecules (Basel, Switzerland)·2025
Same author

Special Issue "Medical Value of Metal Complexes and Plant-Derived Compounds: Biological Evaluation, Health Effects, Challenges, and Future Opportunities".

International journal of molecular sciences·2025
Same author

Monovalent anion-selective membranes fabricated via in situ interfacial polymerization.

Nature communications·2025

Related Experiment Video

Updated: May 11, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Ion pumps as biological targets for decavanadate.

Manuel Aureliano1, Gil Fraqueza, C André Ohlin

  • 1DCBB, FCT, University of Algarve, 8005-139 Faro, Portugal. maalves@ualg.pt

Dalton Transactions (Cambridge, England : 2003)
|May 3, 2013
PubMed
Summary

Polyoxometalates, like decavanadate, show promise as ion pump inhibitors for treating diseases such as cancer. Unlike other inhibitors, decavanadate targets multiple protein conformations, offering a novel therapeutic approach.

More Related Videos

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
06:03

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16

Published on: July 15, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Related Experiment Videos

Last Updated: May 11, 2026

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
06:03

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16

Published on: July 15, 2019

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Polyoxometalates are gaining interest for applications in medicine and biology.
  • Their potential as ion pump inhibitors for treating diseases like cancer and ulcers is being explored.
  • The precise mechanisms of action for many polyoxometalates remain largely unknown.

Purpose of the Study:

  • To review recent findings on the interaction between mono- and polyoxometalate ions and ion pumps.
  • To focus on the interaction of decavanadate with Ca(2+)-ATPase.
  • To compare the proposed mechanisms of polyoxometalates with established ion pump inhibitors.

Main Methods:

  • Review of recent scientific literature on polyoxometalate-ion pump interactions.
  • Focus on decavanadate's interaction with Ca(2+)-ATPase.
  • Comparison of polyoxometalate inhibition mechanisms with existing therapeutic drugs.

Main Results:

  • Most ion pump inhibitors bind to the E2 conformation from the extracellular side.
  • Decavanadate interacts with Ca(2+)-ATPase near the nucleotide binding site or cytoplasmic domains, crossing the membrane bilayer.
  • Decavanadate binds to all Ca(2+)-ATPase conformations (E1, E1P, E2, E2P), unlike monomeric vanadate.
  • Decavanadate's interaction is non-competitive with ATP and induces cysteine oxidation, leading to potent inhibition (IC50 = 15 μM).

Conclusions:

  • Decavanadate exhibits a unique mechanism of ion pump inhibition compared to established drugs.
  • Its ability to bind all protein conformations and induce cysteine oxidation contributes to its high inhibitory capacity.
  • Polyoxometalates, particularly decavanadate, represent a promising class of compounds for therapeutic development against various diseases.